Multiple sclerosis, or MS, is a disease of the immune system that eats away at the fatty coating (called myelin sheath) that protects nerve cells in the brain and spine. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems. Specific symptoms can include double vision, blindness in one eye, muscle weakness, trouble with sensation, or coordination. The effects are often different for everyone who has the disease. Signs and symptoms of MS vary widely and depend on the amount of nerve damage and which nerves are affected. Some people have mild symptoms and don’t need treatment.
Atara (ATA188-MS-101): An Open-Label Phase 1 Study to Evaluate the Safety of ATA188 in Subjects with Progressive and Relapsing-Remitting Multiple Sclerosis
Celgene (RPC-1063): A Multi-Center, Longitudinal, Open-Label, Single-ARM Study Describing, Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod
Novartis CBAF312AUS02 (EXCHANGE): Exploring the safety and tolerability of conversion from oral or injectable disease modifying therapies to dose-titrated Oral Siponimod in patients with advancing forms of relapsing multiple sclerosis: A 6-month open label, multi-center Phase IIIb study
Roche (Verismo): An observational study of Ocrelizumab- treated patients with Multiple Sclerosis to determine the incidence and mortality rates of breast cancer and all malignancies. A 5 year, open label, multi-center, phase IV study
Sanofi (HURCULES): A Phase 3, Randomized, Double-Blind, Efficacy and Safety Study comparing SAR442168 to Placebo in Participants with non-relapsing Secondary Progressive Multiple Sclerosis